TransMedics Group, Inc.TMDX

$78.79+5.57 (+7.61%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$3B
Mid-cap
+468%
2019 — today
10-Year Price
+202%
2019 — today
52-Week Range
$62.04$150.42
Current $78.79· 19%

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Valuation in context

P/E ratio
18.0
Above average
Pricier than usual over the last 10 years
P/B ratio
5.8
Historically cheap
Historically cheap relative to the last 10 years
EV / EBITDA
23.3
Near historic low
Near historic low — last 10 years
FCF Yield
5.3%
Near historic high
Near historic highs — last 10 years
Free · No credit card needed

Get alerted when TMDX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.